 On Nov 14, Stoke Therapeutics reported interim data from their p12 trials in Dravet Syndrome, a severe and progressive genetic epilepsy. Since the news, the stock has declined 41, from 12.49 on Nov 11 to 7.33 on Nov 25. YTD, the stock is down 68. 